FdaApplication
NDA 209091
Identifiers
- fda_app_no: NDA209091
Properties
| Property | Value |
|---|---|
| applicant_name | ASTRAZENECA AB |
| application_type | NDA |
| approval_date | 2017-02-27 |
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| QTERN | DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE | 5MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| QTERN | DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE | 10MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
2 products